Connect with us


Warsaw-based machine learning company selected for EU’s Global Gateway business advisory group

The Global Gateway initiative aims to narrow the global investment gap and mobilise up to €300bn in investments



Urszula Sankowska and Piotr Wygocki, co-founders of MIM Fertility and co-owners of MIM Solutions

The Warsaw-based machine learning company MIM Solutions will represent Poland in EU’s Global Gateway business advisory group.

Global Gateway is a strategy, launched by the European Commission and the EU High Representative, with the aim of boosting smart and secure links in digital, energy and transport sectors and strengthening health, education and research systems.

The mission of the programme is to narrow the global investment gap worldwide, in the light of the recent Covid-19 pandemic and the Russian invasion of Ukraine.

The initiative aims to mobilise up to €300bn in investments through a Team Europe approach, bringing together the EU, its member states and their financial and development institutions.

MIM Solutions, a spin-off of the Faculty of Mathematics, Informatics and Mechanics at the University of Warsaw, uses AI and machine learning to advance outcomes in medicine and reproductive health.

The company has joined the group of advisors to the European Commission alongside giants such as Siemens, Orange, Nokia, and Veolia.

The list of new members of the advisory group was announced on September 18 during the Sustainable Development Goals (SDG) Summit in New York by the EU Commissioner for International Partnerships, Jutta Urpilainen. It included 60 members and 10 observers, representing European companies and business associations.

The Warsaw-based company, managed by Urszula Sankowska and Piotr Wygocki, applied and was selected, primarily due to its expertise in the field of AI.

“We are proud that we will be able to share our knowledge and support the European Commission in implementing the Global Gateway strategy,” shared Wygocki, co-founder and co-CEO of MIM Solutions.

“Our specialisation is AI, which plays a crucial role in democratising access to highly specialised services worldwide.”

Sankowska, co-CEO of MIM Solutions, said: “Our company implements medical solutions based on AI in global markets. Therefore, we have a good understanding of the needs of our partners outside the EU and the necessity to collaborate with them.

“This is an opportunity for us to support the global healthcare initiatives of the Commission and address challenging issues such as infertility treatment.”

The advisory group will play a key role during the Global Gateway Forum, which will take place in Brussels under the leadership of Ursula von der Leyen on October 25-26.

Ursula von der Leyen, president of the European Commission said: “Global Gateway is the EU’s contribution to narrowing the global investment gap worldwide. It offers sustainable investments in the prosperity and security of our partners as well as for Europe.

“To further scale up the Global Gateway flagship projects, we need both public and private resources.

“The Global Gateway business advisory group will help us to work closer together and deliver faster on the green and digital transitions, boosting the economy of our partners and the EU.”


‘Groundbreaking’ endometriosis study identifies patient priorities



A “groundbreaking” study into endometriosis has identified three areas for future research that can help improve the outcomes for women with the condition.

The study, commissioned by Endometriosis New Zealand, attracted 1,262 participants, including 1,024 people with confirmed endometriosis, making it the largest ever study involving endometriosis patients and supporters in New Zealand.

Study participants identified the management and treatment of endometriosis, the need for a better understanding of its cause and improvements to diagnostic capability as the three main priorities for further research.

While these findings provide a clear pathway for future work, Endometriosis New Zealand chief executive, Tanya Cooke, said endometriosis research had historically been underfunded.

“With an estimated 120,000 New Zealanders living with endometriosis, much more needs to be invested into finding solutions,” Cooke explained.

“The reality is the outcomes for many endometriosis patients are pretty poor, with diagnosis often taking many years and treatment patchy across the country.”

Estimates based on Australian data suggest that endometriosis is likely to be costing New Zealand somewhere in the range of $1.3-1.5bn annually through increased healthcare costs and lost workforce productivity.

Cooke said: “The good news is that our findings align closely with those in Australia and provide three clear priorities for future research – improved treatment options, causation and better diagnostic capability.

“What New Zealand now requires is proper funding for a future research programme that can investigate these priorities more closely and improve the outcomes for individuals living with endometriosis.”

To receive the Femtech World newsletter, sign up here.

Continue Reading


Virtual care platform secures US$46m to address US maternal health crisis

Pomelo Care will use the funding to scale its care model and improve maternal and infant outcomes



Marta Bralic Kerns, founder and CEO of Pomelo Care

The US virtual maternity care platform Pomelo Care has secured US$46m in funding to address the US maternal health crisis.

One in 10 babies born in the US today start their life in a neonatal intensive care unit.

Healthcare access continues to worsen, with one in eight births occurring in US counties with limited-to-no access to maternal care. Due to significant gaps in postpartum care, about half of pregnancy-related deaths in the US occur after hospital discharge.

The evidence exists for how to identify people at highest risk for complications and which interventions are most effective, but existing data gaps and provider capacity challenges make it difficult to apply these interventions at scale.

Pomelo has developed a care model that aims to address these challenges by analysing claims and health record data to identify individual risk factors and providing virtual pregnancy, postpartum, and infant care to patients to reduce those risks.

“We’ve long known what works to reduce maternal and infant complications,” said Marta Bralic Kerns, founder and CEO of Pomelo Care.

“The questions have always been: can you identify the patients who are at highest risk, can you deeply engage them in care to drive uptake of the prevention strategies we know work, and can you do it in the highest risk populations with the most limited access to care?”

“This data demonstrates that we absolutely can. And with this additional funding, we’ll have the opportunity to scale our care model to more pregnant people across the country.”

The funding, led by existing investors First Round Capital and Andreessen Horowitz (a16z) Bio + Health, is hoped to help Pomelo accelerate its partnerships with payors across the US and increase access to “evidence-based” care.

Josh Kopelman, partner at First Round Capital and Pomelo board member, said: “It’s rare to come across an opportunity where the incentives between patient, provider and payor are all aligned.

“Marta and the Pomelo team have found an incredible opportunity to dramatically improve outcomes for the highest risk populations, while helping payors reduce their avoidable costs.”

Vineeta Agarwala, general partner at a16z Bio + Health and Pomelo board member, added: “Pomelo is one among a small set of health tech companies that have earned true scale.

“This scale is evident in our partnerships with major Medicaid and commercial plans covering over three million lives, which create the opportunity to collaborate with OB providers, labour and delivery wards, and NICUs nationwide, while serving hundreds of thousands of expecting mothers and newborns with high quality, technology-enabled care.”

To receive the Femtech World newsletter, sign up here.

Continue Reading


One in three UK fertility patients seek treatment abroad due to high costs

Expensive fertility treatments prompt UK patients to seek help abroad



One in three fertility patients in the UK seek treatment abroad due to high costs, a new survey has shown.

Fertility Family has gathered insights from 429 UK participants who have experienced difficulties with infertility.

The Infertility Awareness Report found that the high cost of fertility treatment in the UK has driven over one in four people to spend over £10,000 on both treatments and investigative procedures.

The research showed around 35 per cent of people struggling with infertility have considered seeking fertility treatment abroad due to the prospect of lower costs.

Of those seeking fertility treatment in a foreign country, however, only 14 per cent believed that clinics abroad have a higher success rate.

Of those actively trying to conceive almost one in five have used their life savings in the pursuit of having a child, whilst 25 per cent have paid for their fertility treatments using a credit card.

Dr Gill Lockwood, consultant at Fertility Family, said: “While we tend to cast our gaze on women when it comes to infertility, case studies have shown that infertility can impact both women and men in similar ways. However, women have been observed to seek help more than men.

“Although the psychological struggles of infertility can be overwhelming, many patients ultimately reach some type of resolution. Some of the alternatives include becoming parents to a relative’s children, adopting children, or deciding to adopt a child-free lifestyle.

“Needless to say, this resolution is usually psychologically demanding, and patients may feel forever impacted by the experience of infertility.”

A combination of fertility struggles and accessible healthcare have impacted people across the UK significantly, with one in two admitting to feeling “ashamed” due to their difficulties trying to conceive.

A further 31 per cent reported feeling that other people think “less” of them due to their fertility struggles, showcasing the need for better mental health support.

To receive the Femtech World newsletter, sign up here.

Continue Reading


Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.